Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells 4,125 Shares of Stock

19 Mar 2026, 20:39 by Jessica Moore · The Cerbat Gem

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) General Counsel Bryan Wahl sold 4,125 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $68.71, for a total value of $283,428.75. Following the completion of the sale, the general counsel owned 68,190 shares of the company’s stock, valued at $4,685,334.90. The trade was a 5.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Bryan Wahl also recently made the following trade(s):

On Thursday, March 19th, Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $67.00, for a total value of $283,477.00.
On Tuesday, March 17th, Bryan Wahl sold 4,084 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $69.42, for a total value of $283,511.28.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock traded down $1.49 during mid-day trading on Thursday, hitting $66.75. The company’s stock had a trading volume of 461,600 shares, compared to its average volume of 672,393. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The firm’s 50 day moving average is $69.59 and its 200 day moving average is $70.20.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. lifted its stake in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the last quarter. State of Wisconsin Investment Board increased its position in Tarsus Pharmaceuticals by 1.1% during the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after buying an additional 332 shares during the last quarter. Federated Hermes Inc. increased its position in Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after buying an additional 339 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in Tarsus Pharmaceuticals by 11.1% during the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after buying an additional 392 shares in the last quarter. Finally, Creative Planning lifted its position in shares of Tarsus Pharmaceuticals by 3.3% in the third quarter. Creative Planning now owns 12,367 shares of the company’s stock worth $735,000 after buying an additional 393 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TARS shares. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Mizuho started coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective for the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $91.83.

Get Our Latest Stock Analysis on TARS

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.